Clinical Trials Logo

Clinical Trial Summary

The aim of this observational study is to document the therapeutic use of PASCALLERG ® for hay fever. Based on the survey is a decrease in disease-specific symptoms when taking PASCALLERG ® over a period of 4 weeks will be documented. In addition to the compatibility can be assessed.


Clinical Trial Description

There are documented male and female patients over the age of one year who suffer from hay fever. The traetment time is about a period of 4 weeks with PASCALLERG® tablets. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT01660737
Study type Observational
Source Pascoe Pharmazeutische Praeparate GmbH
Contact
Status Completed
Phase
Start date February 2012
Completion date July 2013

See also
  Status Clinical Trial Phase
Completed NCT00658918 - To Assess the Safety of Ciclesonide, Applied as a Nasal Spray at Three Dose Levels, in the Treatment of Perennial Allergic Rhinitis in Pediatrics (BY9010/M1-405) Phase 3
Active, not recruiting NCT05960266 - Immunological Analysis of Lymph Node Tissue After Intralymphatic Immunotherapy: A Prospective Case Control Study Early Phase 1
Completed NCT00574210 - PK/PD and Steady State Efficacy Study of Bilastine Compared With Placebo Given Orally in the Treatment of the Symptoms of SAR in an EEC Model (5-arm) Phase 2
Completed NCT00384475 - A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-413) Phase 3
Completed NCT06457269 - Evaluating the Potential of Large Language Models for Respiratory Disease Consultations N/A
Completed NCT01506375 - Safety of gpASIT+TM Subcutaneously Administered to Hay Fever Patients With or Without Immunoregulating Adjuvant Phase 2
Completed NCT01137357 - Probiotics for Reduction Of Markers In Subjects With Allergy N/A
Completed NCT00261287 - Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416) Phase 3
Completed NCT00659594 - Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406) Phase 3
Active, not recruiting NCT00247520 - Safety and Efficacy Study of rEV131 in Allergic Rhinitis Phase 1/Phase 2
Completed NCT00163514 - Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403) Phase 3
Completed NCT04326309 - Audio Data Collection for Identification and Classification of Coughing
Completed NCT00305487 - Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417) Phase 3
Completed NCT02932774 - Randomized, Double Blind, Parallel Group, Placebo Controlled, Multi-Center Study of the Efficacy and Safety of Cetirizine HCl Syrup vs. Loratadine Syrup vs. Placebo in Treatment of Children With Seasonal Allergic Rhinitis (SAR) Phase 4
Completed NCT00163488 - Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409) Phase 3
Not yet recruiting NCT03724240 - Clinical Efficacy and Safety of Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis Phase 3
Completed NCT02619331 - Evaluation of High Speed Laser Doppler Imaging Technology N/A
Completed NCT00659503 - Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-407) Phase 3
Completed NCT01024608 - Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR) Phase 3
Completed NCT02560948 - Clinical Efficacy and Safety of a Subcutaneous Immunotherapy With gpASIT+™ in Patients With Grass Pollen-induced Allergic Rhinoconjunctivitis Phase 3